R
Richard B. Moss
Researcher at Stanford University
Publications - 192
Citations - 15123
Richard B. Moss is an academic researcher from Stanford University. The author has contributed to research in topics: Cystic fibrosis & Allergic bronchopulmonary aspergillosis. The author has an hindex of 60, co-authored 186 publications receiving 13934 citations. Previous affiliations of Richard B. Moss include Grant Medical Center & Center for Excellence in Education.
Papers
More filters
Journal ArticleDOI
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
Bonnie W. Ramsey,Jane C. Davies,N. Gerard McElvaney,Elizabeth Tullis,Scott C. Bell,Pavel Dř evínek,Matthias Griese,Edward F. McKone,Claire E. Wainwright,Michael W. Konstan,Richard B. Moss,Felix Ratjen,Isabelle Sermet-Gaudelus,Steven M. Rowe,Qunming Dong,Sally Rodriguez,Karl Yen,Claudia L. Ordoñez,J. Stuart Elborn +18 more
TL;DR: Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks and substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride.
Journal ArticleDOI
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso,Steven M. Rowe,John P. Clancy,Michael P. Boyle,Jordan M. Dunitz,Peter R. Durie,Scott D. Sagel,Douglas B. Hornick,Michael W. Konstan,Scott H. Donaldson,Richard B. Moss,Joseph M. Pilewski,Ronald C. Rubenstein,Ahmet Uluer,Moira L. Aitken,Steven D. Freedman,Lynn M. Rose,Nicole Mayer-Hamblett,Qunming Dong,Jiuhong Zha,Anne Stone,Eric R. Olson,Claudia L. Ordoñez,Preston W. Campbell,Melissa A. Ashlock,Bonnie W. Ramsey +25 more
TL;DR: This study showed that VX-770 was associated with within-subject improvements in CFTR and lung function and provides support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.
Journal ArticleDOI
Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus Conference
David A. Stevens,Richard B. Moss,Viswanath P. Kurup,Alan P. Knutsen,Paul A. Greenberger,Marc A. Judson,David W. Denning,Reto Crameri,Alan S. Brody,Michael J. Light,Marianne Skov,William Maish,Gianni Mastella +12 more
TL;DR: Virulence factors in Aspergillus that could aggravate these diseases, and particularly immunogenetic factors that could predispose persons to ABPA, were identified and diagnostic criteria that could provide a framework for monitoring were adopted.
Journal ArticleDOI
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria
Ritesh Agarwal,Arunaloke Chakrabarti,Anand Shah,Dheeraj Gupta,Jacques F. Meis,Randeep Guleria,Richard B. Moss,David W. Denning +7 more
TL;DR: The importance of recognizing ABPA relates to the improvement of patient symptoms, and delay in development or prevention of bronchiectasis, one manifestation of permanent lung damage in ABPA.
Journal ArticleDOI
Late Pulmonary Sequelae of Bronchopulmonary Dysplasia
William H. Northway,Richard B. Moss,Kathryn B. Carlisle,B. R. Parker,Richard L. Popp,Paul T. Pitlick,Irmgard Eichler,Robert L. Lamm,Byron W. Brown +8 more
TL;DR: Most adolescents and young adults who had bronchopulmonary dysplasia in infancy have some degree of pulmonary dysfunction, consisting of airway obstruction, airway hyperreactivity, and hyperinflation.